CAMBRIDGE, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a commercial stage medical robotics company, today announced that it will be presenting at the 10th annual LD Micro Main Event on Tuesday, December 5th at 9:30 AM PST / 12:30 PM EST at the Luxe Sunset Boulevard Hotel in Los Angeles, CA. Chairman and Chief Executive Officer Paul R. Gudonis will be presenting, as well as meeting with investors.
A live audio webcast of the presentation will be available online at the Investor Relations page of the Company's website. An archive of the event will also be available for those unable to listen live.
The LD Micro Main Event is the largest independent conference for small/micro-cap companies and will feature 250 names presenting to an audience of over 1,000 attendees. In addition, there will be a variety of speakers/panelists discussing topics of interest to investors and issuers, along with coordinate evening events.
About Myomo
Myomo, Inc. is a commercial stage medical
robotics company that offers expanded mobility for those suffering from
neurological disorders and upper limb paralysis. Myomo develops and
markets the MyoPro product line. MyoPro is a powered upper limb orthosis
designed to restore function to the weakened or paralyzed arms of
patients suffering from CVA stroke, brachial plexus injury, traumatic
brain or spinal cord injury, ALS or other neuromuscular disease or
injury. It is currently the only marketed device that, sensing a
patient’s own EMG signals through non-invasive sensors on the arm, can
restore an individual’s ability to perform activities of daily living,
including feeding themselves, carrying objects and doing household
tasks. Many are able to return to work, live independently and reduce
their cost of care. Myomo is headquartered in Cambridge, Massachusetts,
with sales and clinical professionals across the U.S. For more
information, please visit www.myomo.com.
About LD Micro
LD Micro was founded in 2006 with the sole
purpose of being an independent resource in the microcap space. What
started out as a newsletter highlighting unique companies has
transformed into several influential conferences annually.
In 2015, LDM launched the first pure microcap index (the LDMi) to exclusively provide intraday information on the entire sector.
For those interested in attending, please contact David Scher at david@ldmicro.com or visit www.ldmicro.com/events for more information.
Forward Looking Statements
This press release contains
forward-looking statements regarding the Company's future business
expectations, including the therapeutic benefit of the Company’s
products, which are subject to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements are only predictions and may differ materially from actual
results due to a variety of factors. Our actual results could differ
materially from those anticipated in these forward looking statements
for many reasons, including, without limitation, risks related to
regulatory approval and market acceptance of our products, and the other
risk factors contained in our filings made with the Securities and
Exchange Commission. More information about factors that potentially
could affect Myomo's financial results is included in Myomo's filings
with the Securities and Exchange Commission. The Company cautions
readers not to place undue reliance on any such forward-looking
statements, which speak only as of the date made. The Company disclaims
any obligation subsequently to revise any forward-looking statements to
reflect events or circumstances after the date of such statements or to
reflect the occurrence of anticipated or unanticipated events.
